Biotechnology Analyst Minter, along with Dr. Kausik “Kosh” Ray, discuss the upcoming readout of Verve’s Phase I heart-1 Study of VERVE-101 in heterozygous familial hypercholesterolemia (HeFH) on an Analyst/Industry conference call to be held on October 25 at 1:30 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics to present Phase 1b data on HeFH candidate
- Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
- Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
- Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
- Verve Therapeutics names Frederick Fiedorek, M.D., as Chief Medical Officer